Roche GR41987 RHONE-X
Posted by: Georgia Retina in
Research Title: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X) Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI)…
Read MoreSamChungDang SCD411-CP101
Posted by: Georgia Retina in
Research Title: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration Sponsor: Sam Chung Dang Pharm. Co. Ltd. Principal Investigator: Robert A. Stoltz, MD, PhD Description: Age-related macular degeneration (AMD) is a leading cause of vision loss in adults….
Read MoreXbrane XBR1002 XPLORE
Posted by: Georgia Retina in
Research Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration (XPLORE). Sponsor: Xbrane BioPharma AB Principal Investigator: Atul Sharma, M.D. Description: The objectives of this study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (i.e.,…
Read MoreRoche GR40844 LUCERNE
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (LUCERNE) Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in…
Read MoreRoche GR41675 PAVILION
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the…
Read MoreRegeneron VGFTe(HD)-DME-1934 PHOTON
Posted by: Georgia Retina in
Research Title: Sponsor: Principal Investigator: Description: Start Date: Recruitment: Project Personnel: Location(s):
Read MoreNovartis CRTH258B2305 Kingfisher
Posted by: Georgia Retina in
Research Title: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER) Sponsor: Novartis Pharmaceuticals Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: In this 12-month, randomized, double-masked,multicenter, active controlled study, consenting patients will be randomized in a 2:1 ratio (brolucizumab:…
Read MoreNovo Nordisk NN9535-4352 FOCUS
Posted by: Georgia Retina in
Research Title: Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes Sponsor: Novo Nordisk A/S Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2…
Read MoreRoche GR40549 PORTAL
Posted by: Georgia Retina in
Research Title: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) 100 mg/mL with…
Read MoreRoche GR40550 PAGODA
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients with Diabetic Macular Edema (Pagoda) Sponsor: Hoffmann-La Roche Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in…
Read More